College of Veterinary Medicine, Konkuk University, 1 Hwayang-dong, Gwangjin-gu, Seoul, 143-701 Korea.
Poult Sci. 2012 Jan;91(1):66-73. doi: 10.3382/ps.2011-01645.
Polyphenolic compounds present in green tea, particularly catechins, are known to have strong anti-influenza activity. The goal of this study was to determine whether green tea by-products could function as an alternative to common antivirals in animals compared to original green tea. Inhibition of viral cytopathic effects ascertained by neutral red dye uptake was examined with 50% effective (virus-inhibitory) concentrations (EC₅₀)determined. Against the H1N1 virus A/NWS/33, we found the anti-influenza activity of green tea by-products (EC₅₀ = 6.36 µg/mL) to be equivalent to that of original green tea (EC₅₀= 6.72 µg/mL). The anti-influenza activity of green tea by-products was further examined in mouse and chicken influenza infection models. In mice, oral administration of green tea by-products reduced viral titers in the lungs in the early phase of infection, but they could not protect these animals from disease and death. In contrast, therapeutic administration of green tea by-products via feed or water supplement resulted in a dose-dependent significant antiviral effect in chickens, with a dose of 10 g/kg of feed being the most effective (P < 0.001). We also demonstrated that unidentified hexane-soluble fractions of green tea by-products possessed strong anti-influenza activity, in addition to ethyl acetate-soluble fractions, including catechins. This study revealed green tea by-product extracts to be a promising novel antiviral resource for animals.
绿茶中含有的多酚类化合物,特别是儿茶素,具有很强的抗流感活性。本研究的目的是确定与原绿茶相比,绿茶副产物是否可以作为动物中常见抗病毒药物的替代品。通过中性红染料摄取法测定病毒细胞病变抑制作用来确定 50%有效浓度(EC₅₀)。针对 H1N1 病毒 A/NWS/33,我们发现绿茶副产物(EC₅₀=6.36μg/mL)的抗流感活性与原绿茶(EC₅₀=6.72μg/mL)相当。进一步在小鼠和鸡流感感染模型中研究了绿茶副产物的抗流感活性。在小鼠中,绿茶副产物的口服给药在感染早期降低了肺部的病毒滴度,但不能保护这些动物免受疾病和死亡。相比之下,通过饲料或水补充进行绿茶副产物的治疗性给药在鸡中产生了剂量依赖性的显著抗病毒作用,其中以 10 g/kg 饲料的剂量最有效(P<0.001)。我们还表明,除了乙酸乙酯可溶部分包括儿茶素外,绿茶副产物的未知正己烷可溶部分也具有很强的抗流感活性。本研究表明绿茶副产物提取物是一种有前途的新型动物抗病毒资源。